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ABSTRACT: Messenger RNA encoding tumor antigens has the potential to evoke effective 1 
antitumor immunity. This study reports on a nanoparticle platform, named mRNA Galsomes, 2 
that successfully co-delivers nucleoside-modified antigen-encoding mRNA and the glycolipid 3 
antigen and immunopotentiator α-Galactosylceramide (α-GC) to antigen-presenting cells after 4 
intravenous administration. By co-formulating low doses of α-GC, mRNA Galsomes induce a 5 
pluripotent innate and adaptive tumor-specific immune response in mice, with invariant 6 
natural killer T cells (iNKT) as a driving force. In comparison, mRNA Galsomes exhibit 7 
advantages over the state of the art cancer vaccines using unmodified ovalbumin (OVA)-8 
encoding mRNA, as we observed up to seven times more tumor-infiltrating antigen-specific 9 
CTLs, combined with a strong iNKT cell and NK cell activation. In addition, the presence of 10 
suppressive myeloid cells (myeloid-derived suppressor cells and tumor-associated 11 
macrophages) in the tumor micro-environment was significantly lowered. Owing to these 12 
antitumor effects, OVA mRNA Galsomes significantly reduced tumor growth in established 13 
E.G7-OVA lymphoma, with a complete tumor rejection in 40% of the animals. Moreover, 14 
therapeutic vaccination with mRNA Galsomes enhanced the responsiveness to treatment with 15 
a PD-L1 checkpoint inhibitor in B16-OVA melanoma, as evidenced by a synergistic reduction 16 
of tumor outgrowth and a significantly prolonged median survival. Taken together, these data 17 
show that intravenously administered mRNA Galsomes can provide controllable, multi-18 
faceted and effective antitumor immunity, especially when combined with checkpoint 19 
inhibition. 20 
  21 
 3 
Where for long the use of mRNA was limited due to its perceived instability, it is nowadays 1 
possible to successfully deliver mRNA in vivo.
1
 This is strongly supported by two recent 2 
breakthroughs: (i) the packaging of mRNA molecules inside nanoparticles, designed to 3 
improve the selective cell targeting and cytosolic delivery of mRNA 
2-9
 and (ii) the technical 4 
progress in the mRNA construct, including the incorporation of modified nucleotides, 5 
yielding more stable mRNA with an improved translation capacity.
10-13
 Particularly in the 6 
field of vaccination, mRNA encoding antigens has emerged as a versatile and promising 7 
platform.
14
 Preclinical studies and first clinical trials with mRNA-based vaccines have shown 8 




In the field of cancer immunotherapy, Kranz et al. provided first-in-human proof that by 11 
targeting mRNA lipid nanoparticles (LNPs) to dendritic cells (DCs), cytotoxic T cell (CTL) 12 
responses were induced against the encoded tumor antigens.
5
 They and others demonstrated 13 
that besides the successful mRNA expression by DCs, the mode of action of mRNA vaccines 14 
largely depends on the induction of type I interferon (IFN).
6, 17-19
 More specifically, upon 15 
cellular entry, mRNA molecules trigger innate immune activation pathways, including the 16 
endosomal Toll-like receptor (TLR)-7 and cytosolic receptors MDA-5 (melanoma 17 
differentiation-associated protein 5) and RIG-I (retinoic acid-inducible gene I), which results 18 
in type I IFN signaling and the induction of an antiviral immune response. Importantly, 19 
virtually all mRNA vaccines in clinical development rely on this inherent self-adjuvant effect 20 
of mRNA. However, it was shown that type I IFN signaling acts as a double-edged sword as 21 
the evoked immune response prematurely stops mRNA‐translation, thereby lowering antigen 22 
bioavailability.
20, 21
 Moreover, it was suggested that type I IFN, depending on the relative 23 
timing to T cell priming, can either positively or negatively affect T cell responses, with pre-24 
exposure to type I IFN resulting in T cell exhaustion and apoptosis.
22, 23
 In addition, high 25 
 4 
levels of IFN-α can induce adverse effects ranging from flu-like symptoms to autoimmune 1 
sequelae and even life-threatening events.
24, 25
 2 
Besides issues related to vaccine-induced type I IFN secretion, the current mRNA vaccines 3 
often fall short to evoke durable antitumor immunity. Indeed, while mRNA-based cancer 4 
vaccines show optimal properties for the activation of cytotoxic T lymphocyte (CTL) 5 
responses, such as the preferential antigen presentation via MHC-I molecules and the 6 
activation of type I IFN-dependent immunity, the evoked immunity is generally counteracted 7 
by a plethora of tumor-mediated immunosuppressive mechanisms. First of all, tumor cells 8 
may have an impaired or deficit presentation of antigens, making them invisible to CTLs.
26
 9 
Additionally, during an immune attack and as a result of the production of interferons, 10 
immune checkpoint pathways are activated as mechanisms to resist adaptive immunity, such 11 
as the expression of programmed cell death 1 (PD-1) ligand (PD-L1) by tumor cells, antigen-12 
presenting cells (APCs) and its receptor PD-1 on the effector cells.
27-29
 Moreover, tumor-13 
infiltrating CTLs have to deal with immune resistance mediated by various suppressive cells, 14 
including alternatively activated M2 macrophages, myeloid derived suppressor cells 15 
(MDSCs) and regulatory T cells.
30
 Thus, ideally, mRNA vaccines should not solely focus on 16 
the activation of CTLs, but should more broadly harness the host’s immune system to tackle 17 
these different suppressive mechanisms. 18 
To address these issues, continued research is required to develop more safe mRNA vaccines, 19 
while further improving their effectiveness for cancer immunotherapy. Here, we propose an 20 
mRNA nanovaccine, which explores the combined delivery of immunosilent, nucleoside-21 
modified mRNA and the glycolipid -galactosylceramide (α-GC), to achieve broad and 22 
durable, but controllable and effective antitumor immunity. 23 
 5 
By using mRNA containing pseudouridine (Ψ) and 5-methylcytidine (5meC), we choose to 1 
minimize the immune recognition of mRNA and associated anti-mRNA mechanisms and 2 
toxicity issues. As such, we have previously established a liposomal formulation for mRNA 3 
delivery, composed of DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) and cholesterol, 4 
efficiently targeting DCs after intravenous (i.v.). administration. By using nucleoside-5 
modified mRNA, we obtained highly improved mRNA expression levels, while strongly 6 
reducing the release of type I IFN.
31
 7 
In addition, we hypothesized that instead of inducing type I IFN responses, pairing 8 
nucleoside-modified mRNA with α-GC could hold numerous appealing features for cancer 9 
immunotherapy. α-GC is a well-known glycolipid antigen that, when presented by the MHC-10 
I-like molecule CD1d on APCs, leads to the potent activation of invariant natural killer T cells 11 
(iNKT). This subset of unconventional T cells contributes to innate and adaptive immunity, 12 
but can also exert direct and indirect antitumor effects.
32-34
 Unlike the classical immune 13 
adjuvants that directly trigger danger pathways, α-GC exerts an indirect adjuvant effect 14 
through the bidirectional interaction between α-GC-presenting DCs and iNKT cells.
35
 As 15 
such, iNKT cells can activate DCs through the interaction between CD40 and CD40 ligand, 16 
evoking the production of cytokines (e.g., IL-12p70) and expression of co-stimulatory 17 
receptors (e.g., CD80, CD86, and CD70). In turn, when activated, iNKT cells proliferate and 18 
secrete a wide range of cytokines (e.g., IL-2, IFN-γ, IL-4 and TNF-α), which further promotes 19 
the recruitment and activation of DCs, B cells, and T cells. Furthermore, iNKT cells are 20 
known to induce the down-stream activation of NK cells, to exhibit direct tumor killing 21 
effects (e.g., via CD1d recognition) and have been shown to positively modulate tumor-22 
associated macrophages (TAMs) and MDSCs in the tumor microenvironment.
36-39
  23 
In order to efficiently co-deliver nucleoside-modified mRNA and the iNKT ligand α-GC, we 24 
developed a nanoformulation, which will be referred to as “mRNA Galsomes”. The potential 25 
 6 
of this formulation was evaluated by investigating its adjuvancy, the activation of antigen-1 
specific T cell responses, NK- and iNKT cells, and therapeutic effectiveness in two tumor 2 
models. Importantly, the i.v. delivery of mRNA Galsomes was compared to the current “gold 3 
standard” in mRNA vaccination, which is currently under clinical investigation and consists 4 
of LNPs loaded with immunogenic (unmodified) mRNA and therefore rely on the mRNA’s 5 
self-adjuvanticity and corresponding type I IFN to drive immunity.
5
 Finally, we evaluated if 6 
we could further improve the therapeutic outcome by co-administering checkpoint inhibitors 7 
(anti-PD-L1 antibody) to enhance CTL responses and prevent the induction of adaptive 8 
resistance (see Graphical Table of Contents). 9 
RESULTS 10 
mRNA Galsomes: DOTAP-cholesterol liposomes as delivery agent for nucleoside-11 
modified mRNA and α-GC 12 
Previously, we succeeded in developing a liposomal formulation for i.v. injection composed 13 
of DOTAP and cholesterol, that can be used to complex mRNA and retains it full transfection 14 
potential in serum.
31
 DOTAP/cholesterol LNPs loaded with mRNA remain intact in 15 
biologically relevant media, as shown by a stable particle size when incubated in human 16 
serum for up to 24h, and ensure a durable protection of the mRNA cargo from degradation. A 17 
schematic representation of mRNA Galsomes is shown in Figure 1A. We demonstrate that 18 
the physicochemical properties of mRNA Galsomes containing 1 mol% of a-GC were 19 
unaltered compared to mRNA LNPs formulated without α-GC, with a mean size of 190 nm 20 
and a zeta potential of +47 mV (Figure 1B).  21 
By co-formulating the α-GC and the antigen-encoding mRNA in a single nanoparticle system, 22 
it is possible to achieve simultaneous delivery of both components to the same DCs, thus 23 




 T cells on one hand, and the iNKT cells on the other hand. In this regard, it is important 1 
to note that both nanoparticle cargos, mRNA and α-GC, have different requirements regarding 2 
their intracellular delivery. mRNA should escape from the endosomes to the cytoplasm to 3 
allow adequate antigen synthesis by the ribosomes. By contrast, α-GC must accumulate in late 4 
endosomes and lysosomes of DCs, where it is loaded on CD1d molecules and presented to 5 
iNKT cells. As such, we first estimated the delivery efficiency for both mRNA and α-GC, 6 
using DOTAP-cholesterol liposomes as carrier system, and assessed whether or not the 7 
immune response that occurs upon α-GC presentation to iNKT cells affects the mRNA 8 
expression levels. 9 
To evaluate α-GC delivery, bone marrow-derived DCs (BM-DCs) were incubated either with 10 
α-GC alone (dissolved in DMSO) or mRNA Galsomes (containing equal doses of α-GC). 11 
When using BODIPY-labeled α-GC, it was clear that the intracellular delivery of α-GC was 12 
up to ten timer higher by the delivery via mRNA Galsomes (Figure 1C). This was confirmed 13 
by representative confocal microscopy images of BM-DCs after uptake of BODIPY-labeled 14 
α-GC, either by incubation of the cells with α-GC alone or α-GC formulated in mRNA 15 
Galsomes (Supplementary Figure S1). This also translated into an enhanced presentation of 16 
α-GC by CD1d: we observed a threefold increase in the presentation of α-GC via CD1d 17 
complexes compared to α-GC alone (Figure 1D). 18 
To determine the potency of mRNA Galsomes to initiate an immune response, we performed 19 
a dose-response study by injecting mice i.v. with mRNA Galsomes containing a fixed dose of 20 
10 µg mRNA and decreasing doses of α-GC (Figure 1E). Twelve hours post-injection, iNKT 21 
cell activation was measured indirectly by quantifying the levels of IFN- in serum. When 22 
injecting mRNA Galsomes containing 1.4 µg α-GC, a dose which corresponds to the amount 23 
of α-GC that is typically administered systemically in mice, levels of IFN-γ up to 25 000 24 
pg ml
-1
 could be detected in serum.
35
 Although this indicates that mRNA Galsomes are very 25 
 8 
potent to induce immune responses, this coincided with splenomegaly in all of the animals. 1 
However, the levels of IFN-γ could easily be refined by dose adjustments of α-GC. 2 
Importantly, when drastically lower doses were used, down to 20 ng α-GC per mouse (or 3 
0.015 mol% of the total amount of lipids in the nanoparticle), this still resulted in high levels 4 
of IFN-γ (~4000 pg ml
-1
), but without any signs of acute toxicity. Therefore, we used mRNA 5 
Galsomes packaging 20 ng of α-GC for further experiments. 6 
Previous attempts where mRNA was combined with other adjuvants have raised compatibility 7 
issues, since DC maturation can prematurely abrogate cellular uptake mechanisms (e.g., 8 
macropinocytosis) or potentially induce anti-mRNA defense mechanisms (e.g., type I IFN 9 
signaling) leading to fast mRNA degradation.
40, 41
 For these reasons we investigated the 10 
impact of α-GC inclusion on mRNA translation. Firstly, in vitro experiments in murine BM-11 
DCs as well as human monocyte-derived DCs demonstrated that mRNA Galsomes could 12 
efficiently transfect both cell types with eGFP-encoding mRNA in serum-containing medium 13 
(Supplementary Figure S2). In addition, we performed transfection experiments in mice, 14 
using mRNA encoding firefly luciferase (fLuc) as reporter gene. Mice were injected i.v. with 15 
nanoparticles encapsulating different cargos; (i) unmodified mRNA (unmod. mRNA LNPs), 16 
(ii) nucleoside-modified mRNA alone (mod. mRNA LNPs), or (iii) nucleoside-modified 17 
mRNA combined with α-GC (mRNA Galsomes). Bioluminescence was evaluated 6h later. 18 
Figures 1F-G demonstrate that incorporation of α-GC did not interfere with the translation of 19 
mRNA in lungs and spleen, and that increasing mRNA doses up to 10 µg per animal, resulted 20 
in a higher protein expression in the lungs and spleen (Supplementary Figure S3).  21 
As expected, nanoparticles containing unmodified fLuc mRNA display significantly lower 22 
expression levels, which results from their lower intracellular stability, as well as from type I 23 
IFN-mediated antiviral pathways programmed to degrade and avoid the translation of 24 
mRNA.
41
 Together, these results indicate that co-packaging of nucleoside-modified mRNA 25 
 9 
and α-GC improves α-GC delivery and presentation, without affecting the mRNA expression 1 
levels. 2 
 3 
Figure 1. mRNA Galsomes promote the delivery of α-GC to DCs without affecting mRNA 4 
transfection. (A) Schematic representation of a nanoparticle consisting of DOTAP-cholesterol 5 
LNPs, nucleoside-modified mRNA (5meC, ) and the NKT ligand α-GC. (B) Size (Z 6 
average), polydispersity index (PdI) and zeta potential of mRNA LNPs dispersed in HEPES 7 
buffer, formulated with or without α-GC (i.d. 1 mol% of total lipids, n=3). A quantitative 8 
flow cytometric analysis of the increase in intracellular delivery of BODIPY-labeled α-GC 9 
 10 
formulated in mRNA Galsomes is shown in (C), where untreated cells served as negative 1 
controls. (D) Enhanced surface presentation of α-GC in CD1d complexes by BM-DCs 24h 2 
after incubation with α-GC in mRNA Galsomes. (panels C-D show representative data of 3 
three independent experiments, untreated cells serve as negative controls). (E) Dose-response 4 
experiment: IFN-γ levels in serum of C57BL/6 mice 12h after i.v. injection of mRNA 5 
Galsomes containing decreasing doses of α-GC. (F) Graph summarizing whole-body 6 
expression levels of fLuc mRNA in C57Bl/6 mice 6h after i.v. injection of nanoparticles 7 
containing different cargos, or PBS (negative control); liposomes containing unmodified 8 
mRNA, nucleoside-modified- or nucleoside-modified mRNA nanoparticles formulated with 9 
α-GC (n=6-7, pooled from two independent experiments) (G) Representative 10 
bioluminescence images of isolated organs (lungs, spleen and liver). For all these 11 
experiments, mRNA encoding fLuc was used. Statistical analyses on datasets were performed 12 
by One-Way ANOVA followed by Turkey’s post hoc test. Asterisks indicate statistical 13 
significance (n.s., p > 0.05; ***, p < 0.001; ****, p < 0.0001).  14 
mRNA Galsomes mediate strong adjuvant effects and activate dendritic cells in vivo 15 
Immune activation by α-GC is an indirect phenomenon: DCs that present α-GC by CD1d will 16 
stimulate iNKT cells, which, in turn, cause phenotypic maturation of DCs by CD40-CD40-17 
ligand interaction. To assess if this is also the case for mRNA Galsomes, especially with the 18 
low (20 ng) α-GC doses used, we investigated the maturation status of splenic DCs 24h after 19 
particle injection (Figure 2A-B). We could observe a strong and significant up-regulation of 20 
the activation markers CD40 and CD86 on splenic DCs of mice treated with mRNA 21 
Galsomes, relative to untreated mice and mice injected with LNPs containing nucleoside-22 
modified mRNA without α-GC. Importantly, no DC maturation was observed when mRNA 23 
Galsomes were added to BM-DC cultures in vitro, in the absence of iNKT cells. This 24 
 11 
indicates that this in vivo maturation effect was mediated by the ligation with iNKT cells 1 
(Supplementary Figure S4). 2 
To investigate the immune response in more detail, a broad screening of inflammatory 3 
cytokines was performed in blood of animals 6h after vaccination (Figure 2C). As expected, 4 
nanoparticles containing unmodified mRNA induced a strong release of IFN-α, while this was 5 
not the case with nucleoside-modified mRNA nanoparticles (with or without α-GC). By 6 
contrast, mRNA Galsomes induced a pronounced production of IFN- and IL-4. What is 7 
more, in the group receiving mRNA Galsomes, we could also detect the presence of T cell-8 
stimulating cytokines, such as IL-12p70 and IL-27, and elevated levels of IL-6, TNF and IL-9 
17. Importantly, this broad spectrum of cytokines did not induce visible toxicity symptoms 10 
(changes in body condition score, behavior, global appearance or posture) and no pathological 11 
changes were identified in H&E stained organ sections of lungs, spleen and liver, while 12 
normal levels of ALT activity were measured (Supplementary Figure S5). 13 
 12 
 1 
Figure 2. mRNA Galsomes containing low doses of α-GC (20 ng) induce the maturation of 2 
dendritic cells in vivo and stimulate the release of immunostimulatory cytokines. (A) Splenic 3 
DCs (CD11c
+
) showed an increase in the expression of the activation markers CD40 and 4 
CD86 (expressed as a fold change in MFI) 24h after administration of mRNA Galsomes, 5 
while incomplete maturation was observed with nanoparticles containing nucleoside-modified 6 
 13 
mRNA alone (n=4). (B) Representative histograms of CD40 and CD86 expression by CD11c
+
 1 
cells. (C) Serum samples were collected at 6h post-injection and screened for the release of 2 
inflammatory cytokines: while nanoparticles containing unmodified mRNA trigger the 3 
production of IFN-, mRNA Galsomes induce distinct cytokine responses, including IFN-, 4 
IL-4, IL-12p70, IL-27, IL-17a, IL-6 and TNF-. For all experiments in this figure, fLuc 5 
mRNA was used. Data are pooled from at least two independent experiments. Mice injected 6 
with PBS serve as negative controls. Statistical analyses on datasets were performed by One-7 
Way ANOVA followed by Turkey’s post hoc test. Asterisks indicate statistical significance 8 
compared to negative control (****, p < 0.0001). 9 
mRNA Galsomes as pluripotent inducers of immunity 10 
One could expect that the increased mRNA expression levels combined with strong DC 11 
maturation, and the production of CTL-inducing cytokines such as IL-12p70, hold potential 12 
for mRNA Galsomes to compete with type I IFN-dependent mRNA vaccines. In addition to T 13 
cell-mediated immunity, the combination with α-GC could also offer the advantage of 14 
activating both iNKT- and NK cells shaping a broader and potentially synergistic antitumor 15 
immunity.  16 
To evaluate these multiple effector responses, animals were immunized with mRNA encoding 17 
chicken ovalbumin (OVA) as a model antigen. Six days after immunization, cell numbers of 18 
OVA-specific CTLs were measured in isolated spleens (Figure 3A-B). Interestingly, we 19 
observed that mRNA Galsomes generated four to five times higher levels of OVA-specific 20 
CTLs compared to mice treated with nanoparticles containing unmodified OVA mRNA.  21 
To evaluate the proliferation of iNKT and down-stream NK cell responses, spleen and liver 22 
were isolated three days after vaccination. Corresponding to the cytokine responses (Figure 23 
2B), we observed an increased proliferation of iNKT cells, from 0.8 to 2.3% in spleen and 4.4 24 
 14 
to 14% in liver (Figure 3C-D). Accordingly, mRNA Galsomes also mediated the 1 
proliferation of NK cells as their levels increased from 2.2 to 3.8 % and 4.7 to 12%, in spleen 2 
and liver, respectively. (Figure 3E).  3 
 4 
Figure 3. mRNA Galsomes mediate pluripotent innate and adaptive immune responses. (A) 5 
mRNA Galsomes strongly mediate the induction of antigen-specific CD8
+
 T cell responses. 6 
Mice were immunized with OVA mRNA LNPs. Six days later, percentages of OVA-specific 7 
splenic CD8
+
 T cells were measured using an H-2kb OVA tetramer staining. (B) 8 
Representative flow cytometry scatter plots of OVA-specific CD8
+
 T cells. Blue events 9 
represent tetramer-stained CD8
+ 
cells. (C) Three days post-injection of mRNA Galsomes, 10 
 15 
spleen and liver displayed expanded iNKT cell numbers compared to untreated mice. (D) 1 









 cells). The 3 
data in this figure (n=6) are pooled from two independent experiments. PBS-injected mice 4 
serve as negative controls. Statistical analyses on datasets were performed by One-Way 5 
ANOVA followed by Turkey’s post hoc test for (A). Pairwise comparisons in sections (C) 6 
and (E) were performed via a student’s t test. Asterisks indicate statistical significance (**, p 7 
< 0.01; ****, p < 0.0001). 8 
Therapeutic efficacy of mRNA Galsomes in E.G7-OVA lymphoma- and B16-OVA 9 
melanoma  10 
To assess the potential of mRNA Galsomes in a therapeutic vaccination study, mice were 11 
subcutaneously inoculated with OVA-expressing E.G7 lymphoma cells or B16-OVA 12 
melanoma cells and vaccinated when tumors were palpable at day 8 with mRNA encoding 13 
OVA.  14 
E.G7-OVA bearing mice were treated with a single administration of either mRNA Galsomes 15 
or nanoparticles containing unmodified mRNA, in order to differentiate between the 16 
therapeutic potential of nanoparticles that evoke immunity based on iNKT cell activation or a 17 
type I IFN response, respectively. First of all, both therapies resulted in a significant reduction 18 
in tumor growth and prolonged survival, relative to untreated mice (Figure 4A-B). Overall, 19 
mice treated with nanoparticles containing unmodified mRNA, showed complete tumor 20 
regression in 4/6 animals, and treatment with mRNA Galsomes resulted in complete tumor 21 
regression in 3/7 animals, and no significant differences could be observed in tumor growth 22 
between both treatment groups. It should be noted that nucleoside-modified mRNA 23 
 16 
nanoparticles without α-GC did not have significant effects on tumor growth 1 
(Supplementary Figure S6). 2 
In a more aggressive B16-OVA melanoma model, animals received three administrations of 3 
either mRNA Galsomes or umodified mRNA nanoparticles on day 8, day 12 and day 16 after 4 
tumor inoculation. Although we observed a delay of tumor outgrowth, there was only a 5 
modest prolongation of survival for mice treated with mRNA Galsomes or nanoparticles 6 
containing unmodified mRNA, with median survival of 28 days and 29 days, respectively, 7 
compared to 22.5 days for untreated animals (Figure 4C-D). In addition, we noticed that 8 
multiple doses could not efficiently boost or prolong the antitumor responses. This also 9 
occurred in the E.G7-OVA model, where a second (boost) vaccination did not result in better 10 
control of tumor outgrowth (Supplementary Figure S7). 11 
 12 
 17 
Figure 4. Therapeutic vaccination with OVA mRNA Galsomes or nanoparticles containing 1 
unmodified OVA mRNA in E.G7-OVA lymphoma and B16-OVA melanoma model. Mice 2 
were subcutaneously inoculated with E.G7-OVA cells or B16-OVA cells (3x10
5 
cells). E.G7-3 
OVA bearing mice were vaccinated on day 8 when tumors were clearly visible. B16-OVA 4 
bearing mice received three vaccinations on day 8, day 12 and day 16. Graphs show Kaplan–5 
Meier survival curves in E.G7-OVA model (A) and B16-OVA model (C), and the respective 6 
tumor growth curves (B and D) as a function of time for an untreated control group (negative 7 
control), and for mice treated with OVA mRNA Galsomes or nanoparticles containing 8 
unmodified OVA mRNA (n=7-8). Statistical analysis on the survival curves (A) and (C) was 9 
performed using a log-rank (Mantel–Cox) test. In (B) and (D), tumor volumes measured at 10 
day 25 were compared by a One-way ANOVA followed by Tukey's post hoc test. Asterisks 11 
indicate statistical significance compared to the untreated group (* p < 0.05; **, p < 0.01; ***, 12 
p < 0.001; **** p < 0.0001) 13 
mRNA Galsomes promote the tumor infiltration of CTLs, iNKT cells and NK cells, but 14 
immune surveillance is hampered by the PD-1/PD-L1 axis 15 
Since complete control of tumor outgrowth was not achieved, we aimed to investigate which 16 
immune suppressive mechanisms might be at play to counteract the evoked antitumor 17 
immunity by mRNA Galsomes or nanoparticles containing unmodified mRNA. Therefore, 18 
experiments were performed where B16-OVA bearing mice were euthanized two days after a 19 
second nanoparticle administration (day 14), and a detailed analysis of the tumor immune 20 
microenvironment was performed. Tumor and spleen were screened for effector responses 21 
and/or suppressive mechanisms that could impact the therapeutic outcome. The most 22 
important findings are shown in Figure 5. The flow cytometry gating strategy for each cell 23 
type can be found in Supplementary Figure S8. 24 
 18 
First of all, animals treated with mRNA Galsomes exhibited up to five times higher levels of 1 
tumor infiltrating OVA-specific CTLs, whereas CTL presence at the tumor site merely 2 
doubled after vaccination with nanoparticles containing unmodified mRNA compared to the 3 
untreated group (Figure 5A). Likewise, vaccinations with mRNA Galsomes resulted in six to 4 
seven times higher numbers of CTLs specific for OVA (10% of viable cells in tumor, as 5 
determined by SIINFEKL-H2Kb tetramer staining) compared to animals treated with 6 
nanoparticles containing unmodified mRNA, while almost no (< 0.04 %) OVA-specific CTLs 7 
were detected in the tumors of the untreated animals (Figure 5B). In addition, we detected a 8 
fourfold increase in iNKT cell numbers in the tumors of mice treated with mRNA Galsomes, 9 
compared to the other groups (Figure 5C). For both treatments, increased levels of tumor-10 
infiltrating NK cells were observed, with ± 13% NK cells for mRNA Galsomes and ± 11% 11 
NK cells for nanoparticles containing unmodified mRNA compared to untreated mice with 12 
only ± 5% NK cells (Figure 5D). By analyzing the tumor site for suppressive immune cells, 13 







 cells) compared to untreated controls. Interestingly, this rise in 15 
MDSC levels was not observed in animals treated with mRNA Galsomes (Figure 5E). 16 




 cells) in the mRNA 17 
Galsome-group displayed a pro-inflammatory M1-like phenotype, marked by increased levels 18 
of MHC-II (Figure 5F).  19 
While vaccination with mRNA Galsomes resulted in “hot“ T cell-infiltrated tumors, we 20 
investigated whether immune suppression via the PD-1/PD-L1 axis could be involved in 21 
countering the vaccine-induced immune response.
29
 As shown in Figure 5G, LNP 22 
vaccination caused a significant up-regulation of PD-1 on the activated OVA-specific splenic 23 
CTLs compared to CTLs of untreated mice. These increased PD-1 levels were comparable for 24 
mice injected with mRNA Galsomes or LNPs containing unmodified mRNA. Within the 25 
 19 
tumor, PD-1 levels on intratumoral CTLs are up to 10 times higher compared to CTLs in the 1 
spleen for untreated animals. Although PD-1 expression levels on intratumoral CTLs are 2 
lower in vaccinated animals, it remains obvious that in this microenvironment, the influence 3 
of the PD-1/PD-L1 axis is much more pronounced compared to the spleen. A different 4 
situation is observed for iNKT cells. As shown in Figure 5H, mRNA Galsomes not only 5 
trigger the proliferation of splenic iNKT cells, but this coincides with a doubling in their PD-1 6 
expression levels. LNPs containing unmodified mRNA without α-GC, did not have this 7 
effect. Within the tumor, the crosstalk between iNKT cells and the tumor microenvironment 8 
once more results in stronger PD-1 expression in all treatment groups. This PD-1 up-9 
regulation on previously activated iNKT cells matches previous reports where inhibitory 10 
signals via the PD-1/PDL-1 pathway were suggested to play a role in the loss of 11 
responsiveness to subsequent α-GC stimulations after (over-) stimulation. Moreover, this is in 12 
line with the limited boost-effect we observed upon multiple injections of the mRNA 13 
Galsomes (Figure 4C-D). 14 
In addition to expression levels of PD-1, we measured the presence of its ligand on DCs (in 15 
spleen and tumor), as well as on tumor cells, specifically for mRNA Galsomes 16 
(Supplementary Figure S9). Similar to other reports, we observed that 37.5 ± 4.9 % of 17 
splenic DCs up-regulated the expression of PD-L1 after vaccination with mRNA Galsomes. 18 
Similar to what we observed for intratumoral PD-1 levels, DCs within the tumor exhibit much 19 
higher basal levels of PD-L1, which are further increased upon mRNA Galsome vaccination. 20 
When evaluating the tumor cells’ PD-L1 levels, a fourfold increase in expression could be 21 
observed in animals treated with mRNA Galsomes compared to untreated controls.  22 
Taken together, these findings demonstrate that the inhibitory PD-1/PD-L1 immune 23 
checkpoint axis is involved in the suppression of CTLs, and that it could potentially explain 24 
 20 
the limited responsiveness of iNKT cells to a second (boost) vaccination, thus limiting 1 
antitumor immunity. 2 
 3 
Figure 5. Therapeutic vaccination with mRNA Galsomes attracts immune effector cells to the 4 
tumor and positively affects suppressive myeloid cells in B16-OVA melanoma. B16-OVA 5 
bearing mice which received two vaccinations with OVA mRNA Galsomes were euthanized 6 
 21 
on day 14 and evaluated for infiltration CD8
+ 
T cells (A) and OVA-specific CD8
+
 T cells (B), 1 






) and (F) 2 






) in tumor site (n=8, pooled from two 3 
independent experiments). (G) PD-1 expression on splenic and tumor-infiltrating OVA-4 
specific CD8
+ 
T cells at day 14 (two days after boost) (n=4-6). (H) PD-1 expression levels on 5 
(activated) iNKT cells in spleen and B16-OVA tumors at day 14 (n=5-8, pooled from two 6 
independent experiments). Statistical analyses on datasets were performed by One-Way 7 
ANOVA followed by Turkey’s post hoc test. Asterisks indicate statistical significance 8 
compared to the untreated group (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). 9 
Anti-PD-L1 checkpoint blockade synergizes with the antitumor effects of mRNA 10 
Galsomes 11 
To first investigate the problem of iNKT anergy in more detail, naive mice were vaccinated 12 
twice with mRNA Galsomes with a five day interval. At respectively 6h and three days after 13 
each administration, we evaluated the cytokine release and iNKT activation. As shown in 14 
Figure 6A, IFN- levels measured after the second vaccination, were only half of the levels 15 
measured after the first administration. In addition, we could observe a shift towards the 16 
production of IL-4 and IL-10, which counteract Th1 and therefore CTL responses 17 
(Supplementary Figure S10). Finally, we noticed that a boost-vaccination with mRNA 18 
Galsomes did not further augment iNKT cell numbers, confirming the induction of a hypo-19 
responsive state of iNKT cells. In shear contrast, when mice were simultaneously vaccinated 20 
and injected with an anti-PD-L1 antibody, IFN- production rose up to four times higher after 21 
the second vaccination, compared to that after the initial challenge. Along the same line, the 22 
combination with an anti-PD-L1 antibody further boosted the expansion of iNKT cells, as a 23 
second administration doubled the number of splenic iNKT cells (2.25 ± 0.7 versus 4.73 ± 1.2 24 
%, Figure 6B). Evaluation of PD-L1 on splenic DCs showed that the previously observed up-25 
 22 
regulation of this molecule upon mRNA Galsome vaccination could be fully eliminated by the 1 
concomitant delivery of an anti-PD-L1 antibody (Figure 6E).
42, 43
 In addition, these data 2 
show that repeated activation of iNKT cells by the mRNA Galsomes/checkpoint combination 3 
strategy is feasible, as the PD-1 levels on iNKT cells were halved compared to levels in mice 4 
that merely received a single vaccination with mRNA Galsomes alone (Figure 6C). 5 
To evaluate if the above-mentioned effects of the combination therapy could also be 6 
translated into an improved therapeutic outcome, B16-OVA bearing mice were vaccinated 7 
with mRNA Galsomes combined with intraperitoneal (i.p.) administrations of either an anti-8 
PD-L1 antibody or an isotype control antibody. Monotherapy of an anti-PD-L1 or isotype 9 
control antibody was used as additional controls. The results in Figure 6D show that by the 10 
time of the last vaccination (day 22), the average tumor volume of mice treated with a 11 
combination of mRNA Galsome and a checkpoint blocking antibody, remained limited to 59 12 
± 46 mm
3
. By contrast, in all other groups, tumors had already grown up to 10 times larger. 13 
This also translated into a significant increase in median survival. Mice receiving 14 
monotherapy of an anti-PD-L1 antibody or mRNA Galsomes had reached their median 15 
survival at day 21 and 22.5, respectively, which is not significantly later than animals in the 16 
control group where only an isotype control antibody was injected (median survival of 19 17 
days). The combination treatment significantly prolonged median survival to 30 days, 18 
indicating a synergistic effect between both treatment strategies.  19 
Overall, we clearly show that the therapeutic potential of mRNA Galsomes can be 20 
strengthened by rationally combining with PD-L1 checkpoint inhibition. This checkpoint 21 
blockage (1) prevents the induction of iNKT anergy allowing multiple vaccination rounds, 22 
and (2) avoids adaptive resistance mechanisms at the tumor site prolonging antitumor effects 23 
and promoting the survival of B16-OVA tumor-bearing mice. 24 
 23 
 1 
Figure 6. Checkpoint inhibition with an anti-PD-L1 antibody prevents the induction of iNKT 2 
anergy and avoids adaptive resistance to antitumor effects of mRNA Galsomes. For the 3 
evaluation of iNKT anergy, naive mice received two subsequent injections with OVA mRNA 4 
Galsomes at a five day interval. (A) Graph showing IFN-γ levels in serum, collected 6h after 5 
the first and second administration of mRNA Galsomes combined with either isotype or anti-6 




 cells) 7 
among splenocytes, measured three days after each vaccination. (C) PD-L1 expression on 8 
splenic DCs (CD11c
+
 cells) and PD-1 expression on proliferated iNKT cells, measured 6h 9 
after the first and three days after the second vaccination, respectively (n=3-4). B16-OVA 10 
bearing mice were i.p. administered with 100 µg of a rat IgG2b antibody (isotype control) or 11 
anti-PD-L1 antibody in monotherapy, or in combination therapy with mRNA Galsomes. 12 
Graph (D) shows average tumor growth curves and (E) Kaplan–Meier survival curves for 13 
respective treatments, demonstrating synergistic effects between the anti-PD-L1 antibody and 14 
mRNA Galsomes (n=6-8). Black arrows indicate the days of treatment with both i.v. mRNA 15 
 24 
Galsomes and i.p. antibody. Blue arrows indicate when only antibody was injected (i.p.). 1 
Pairwise statistical analysis in (A) and (B) were performed using a student’s t test. For (D), 2 
tumor volumes at day 22 after tumor inoculation were compared by a One-way ANOVA 3 
followed by Tukey's post hoc test. Asterisks indicate statistical significance compared to the 4 
untreated group (n.s., p > 0.05; * p < 0.05; **, p < 0.01; ***, p < 0.001). 5 
 6 
DISCUSSION 7 
In this study, we report on the use of an mRNA nanovaccine that is capable of inducing a 8 
broad set of antitumor effector cells, including CTLs, iNKT cells and NK cells, while 9 
reducing local immune suppression at the tumor site. This was achieved by co-packaging 10 
nucleoside-modified mRNA encoding tumor antigens and the glycolipid α-GC, which 11 
functions as an iNKT cell agonist and broadly acting immune adjuvant.  12 
In the specific case of cancer immunotherapy, it was proven essential to evoke a systemic 13 
immune response to obtain antitumor immunity, which makes i.v. delivery the preferred 14 
administration route for mRNA-based cancer vaccines.
5, 7, 44
 In our previous research, we 15 
showed that DOTAP-cholesterol nanoparticles could efficiently deliver mRNA to DCs and 16 
macrophages in lungs and spleen after systemic delivery.
31
 By introducing modified 17 
nucleotides in the mRNA construct, the stability and translation are enhanced, resulting in 18 
higher and more sustainable mRNA expression levels. This enhanced mRNA expression is 19 
advantageous in the development of vaccines, since the resulting increased antigen 20 
presentation is shown to be beneficial for the induction of long-lived antibody and helper T 21 
cell responses, including the formation of follicular T cells.
45
 However, nucleoside-modified 22 
mRNA largely loses its self-adjuvancy, resulting in reduced type I IFN levels, and a limited 23 
 25 
capacity to evoke CTL immunity. To compensate for this, vaccines based on immunosilent 1 
mRNA require additional immune stimulation, which we provided by including α-GC.
6, 31
 2 
We demonstrated that by embedding the glycolipid α-GC within mRNA DOTAP-cholesterol 3 
nanoparticles, the delivery of α-GC and its subsequent CD1d-mediated presentation were 4 
enhanced, while the mRNA transfection remained equally high (Figure 1). In all likelihood, 5 
this can be attributed to a difference in cellular uptake, which largely determines the 6 
trafficking and loading into CD1d. Exogenous glycolipid antigens, can either directly 7 
associate with cell surface-bound CD1d or, when these lipids are present in the 8 
endolysosomal compartments, they can be complexed with CD1d, which is being recycled 9 
from the plasma membrane through the endosomes and lysosomes.
46
 Especially this last form 10 
of α-GC-CD1d complexation is interesting, as Torreno-Pina demonstrated that this process 11 
results in the formation of nanoclusters of CD1d-loaded α-GC at the APC’s surface, a process 12 
referred to as “lipid-raft mediated CD1d presentation”.
47
 Since the occurrence of larger 13 
nanoclusters is correlated with enhanced iNKT cell stimulation, superior DC licensing and 14 
improved transactivation of bystander NK cells, this pathway will likely proved the strongest 15 
immune adjuvant effect.
48, 49
 Taken together, it is likely that by particulating α-GC, it is 16 
preferentially trafficked through the endolysosomes, not only enabling a higher intracellular 17 
presence, but also resulting in superior lipid antigen presentation. 18 
As a result of this enhanced α-GC presentation capacity, mRNA Galsomes containing low 19 
doses of α-GC were able to trigger the stimulation of iNKT cells in vivo, which rapidly 20 
induced the maturation of transfected APCs and coincided with the release of a plethora of 21 
cytokines (Figure 2). Shortly after the systemic delivery of mRNA Galsomes, we detected 22 
high levels of the Th1 cytokines IFN-γ, TNF-α and IL-12p70, as well as of the Th2 cytokines 23 
IL-6 and IL-4. Similar to type I IFN, IL-12p70 acts as a “third signal cytokine”, promoting the 24 
activation and survival of T cells 
50
. We also detected high levels of IL-27, a stimulatory 25 
 26 
cytokine that plays a pivotal role in the expansion and programming of T cells, and is 1 
involved in the regulation of NK and iNKT cells and their recruitment to the tumor site.
51-53
 In 2 
connection herewith, Semmling et al. demonstrated that DCs licensed by iNKT cells recruited 3 
CTLs via a particular chemokine mechanism, comprising the production of CCL17 and the 4 
expression of CCR4.
54, 55
 They showed that CCL17 acted synergistically with other 5 
chemokine pathways, resulting in more rapid and improved CTL responses. Indeed, we 6 
showed that vaccination with mRNA Galsomes resulted in approximately five times more 7 
antigen-specific CTLs compared to LNPs loaded with unmodified mRNA (Figure 3).  8 
With respect to the therapeutic effects of mRNA Galsomes, we could determine a switch from 9 
a tumor-promoting towards a more antitumoral immune infiltrate within the tumor. First of 10 
all, we observed significantly higher levels of CTL, iNKT and NK cell levels after 11 
vaccination with mRNA Galsomes, compared to vaccination with gold standard particles 12 
containing unmodified mRNA (Figure 3). In this regard, it is important to consider that even 13 
without specifically targeting NK and iNKT cells in the vaccine design, it is known that these 14 
cells contribute to the outcome of therapeutic vaccines. As such, Fotin-Mleczek et al. showed 15 
that depletion of NK and iNKT cells via NK1.1 antibodies, partially reduced the antitumor 16 
effects of an mRNA vaccine encoding OVA in E.G7-OVA lymphoma implanted mice.
56
 17 
Therefore, the specific stimulation of iNKT responses by including glycolipid antigens can be 18 
expected to enhance the vaccine effect. Indeed, we observed a more favorable, antitumoral 19 
immune infiltrate in B16-OVA tumors treated with mRNA Galsomes compared to 20 
nanoparticles containing unmodified mRNA (Figure 5). mRNA Galsomes evoked a stronger 21 
infiltration of effector immune cells, with seven times more OVA-specific CTLs and 22 
approximately four times more iNKT cells. For NK cells, we found that the cell numbers in 23 
mRNA Galsomes-treated tumors had more than doubled compared to untreated controls, 24 
which matched levels evoked by vaccination with unmodified mRNA. 25 
 27 
A second observation was the reduced presence of immunosuppressive tumor-infiltrating cells 1 
(Figure 5). To exemplify, mRNA Galsomes positively modulated suppressive myeloid cells in 2 
B16-OVA tumors, as demonstrated by the reduced infiltration of MDSCs and TAMs and their 3 
increased expression levels of MHC-II. These observations can be further explained by the 4 
research of Cortesi et al., who evidenced that iNKT cells could, via CD1d and CD40/Fas-5 
dependent cell interactions, selectively kill M2-like macrophages, while promoting the 6 
survival of M1-like macrophages.
37
 Moreover, it was shown that iNKTs can mediate the 7 
conversion of immunosuppressive MDSCs into immunogenic APCs in a CD1d-dependent 8 
manner.
36
 In addition, multiple studies provided evidence that the cytokine responses to α-GC 9 
have the capacity to restore the functionality of tumor-suppressed DCs and exhausted CTLs, 10 
breaking local tolerance in the tumor microenvironment.
53, 57
 11 
Despite these promising changes in the tumor immune infiltrate, mRNA Galsomes merely had 12 
a limited impact on tumor progression and survival of B16-OVA-bearing mice, which was 13 
comparable to the effects of gold-standard nanoparticles containing unmodified mRNA 14 
(Figure 4). In part, this could be linked to the observation that repeated vaccinations with 15 
mRNA Galsomes did not exert a boost effect on tumor reduction, nor did it evoke further 16 
expansion of iNKT cells. This strongly suggested the induction of a hypo-responsive or 17 
anergic state, which was previously reported to occur after strong iNKT activation by α-18 
GC.
58-60
 This anergy is generally characterized by the impaired production of Th1 cytokines 19 
and reduction in iNKT cell numbers upon re-stimulation. While literature contains conflicting 20 
data about iNKT anergy, multiple studies reported that the PD-1/PD-L1 checkpoint pathway 21 
plays a critical role in regulation of iNKT cell activity.
42, 57, 61
 When investigating the 22 
involvement of this checkpoint axis in the present study, we confirmed the up-regulation of 23 
PD-1 in activated NKT cells, as well as its ligand PD-L1 in APCs in the systemic organs 24 
(Figure 5 and Figure S9). We could also detect a pronounced PD-L1 expression in tumors of 25 
 28 
nanoparticle-treated animals. This coincided with high PD-1 expression levels on OVA-1 
specific tumor infiltrating CTLs, which was both the case for animals treated with mRNA 2 
Galsomes and LNPs containing unmodified mRNA. This is consistent with recent research by 3 
Sayour et al., who reported that i.v. administered DOTAP LNPs containing unmodified 4 
mRNA increased the levels of PD-L1 on myeloid cells in the systemic organs and in the 5 
tumor micro-environment.
62
  6 
The identification of PD-1/PD-L1-mediated adaptive resistance as one of the culprit 7 
mechanisms that hamper the antitumoral effects of T cells and iNKT cells, also offers an 8 
additional therapeutic point of engagement.
62-64
 Consequently, we tested the combination of 9 
mRNA Galsomes with i.p. administration of an anti-PD-L1 antibody (Figure 6). Indeed, the 10 
combination therapy showed clear synergistic antitumor effects in every treated mouse, while 11 
mRNA Galsomes and the anti-PD-L1 antibody in monotherapy only exerted antitumor effects 12 
in a small portion of animals. Additionally, we could demonstrate that the administration of 13 
an anti-PD-L1 antibody at the same time as the mRNA Galsome vaccine, prevented the 14 
induction of iNKT anergy, and allowed to boost the stimulation of iNKT cells after successive 15 
administrations. These findings confirm previous observations made by Parekh et al. 16 
combining unformulated α-GC with antibodies directed against PD-L1 and PD-L2.
42
 17 
Importantly, one should bear in mind that recent studies suggest that the up-regulation of PD-18 
1 by iNKT cells is only a small part of a complex immune cascade, involving different 19 
signalling pathways.
65-68
 For instance, some reports showed associations between Wnt/β-20 
catenin signalling and the regulation of cytokine responses by iNKT cells. More specifically, 21 
Kling et al. showed that upon challenge with α-GC, β-catenin activity rapidly suppresses the 22 
production of IFN-γ by iNKT cells in liver, while IL-4 production is promoted.
67
 In addition, 23 
Berga-Bolaños et al. demonstrated that β-catenin expression promotes the development of 24 
iNKT2 and iNKT17 subsets in the thymus, at the expense of iNKT1 cells, potentially 25 
 29 
explaining the polarization towards the production of Th2-biased cytokines upon sequential α-1 
GC stimulations.
68
 Taken together, it is likely that by also counteracting these other 2 
suppressive mechanisms, iNKT cell anergy and the resistance to the therapeutic effects of 3 
mRNA Galsomes, could be further tuned down.  4 
Finally, it is important to consider that B16-OVA tumor cells are notorious for their low 5 
expression of CD1d, which makes them poor targets for direct killing by iNKT cells. The 6 
mode of action of the mRNA Galsomes in this model is therefore expected to be almost 7 
exclusively determined by the indirect effects of iNKT activation: (i) the licensing of DCs by 8 
iNKT cells, (ii) the promotion of CTL responses and NK cell responses, and (iii) the 9 
beneficial interactions between iNKT cells and suppressive myeloid cells in the tumor micro-10 
environment.
32-34
 Therefore, we would like to stress that it is likely that the true value of the 11 
mRNA Galsomes will probably lie in the treatment of tumors where direct iNKT cell-12 
mediated killing effects can occur. For example, in most blood cancers, such as lymphomas, 13 
tumor cells express CD1d, which makes them vulnerable to direct killing effects of iNKT 14 
cells.
69-71
 Also, renal cell carcinoma, colorectal carcinoma and some brain cancers (e.g., 15 
malignant glioma and in some cases of medullablastoma) were shown to be CD1d positive, 16 





Taken together, we have developed a flexible and versatile mRNA nanoparticle platform that 20 
presents an attractive way of initiating tumor immunity by targeting and activating 21 
conventional T cells and iNKT cells directly in vivo. Importantly, by combining immune-22 
silent mRNA with the iNKT ligand α-GC in a single particle, a broad, yet safe, effective and 23 
controllable immune response can be evoked in different tumor models. In combination 24 
 30 
therapy with PD-1/PD-L1 checkpoint inhibition, mRNA Galsomes hold potential to achieve 1 
effective antitumor immunity, this by preventing the induction of iNKT anergy, as well as by 2 
overcoming adaptive resistance at the tumor site. 3 
 4 
EXPERIMENTAL 5 
Cell culture and mice 6 
Female C57BL/6 mice (6 weeks old) were purchased from Envigo (Gannat, France) and 7 
housed in an SPF facility. All animal experiments were conducted according to the 8 
regulations of the Belgian law and approved by the local Ethical Committee. Primary murine 9 
bone marrow-derived DC (BM-DC) cultures were generated as previously described.
31
 10 
Briefly, bone marrow was isolated from the femurs and tibias and processed into a single cell 11 





), 1% penicillin/streptomycin/L-glutamin (Gibco-13 
Invitrogen), β-mercaptoethanol (5 µM, Gibco-Invitrogen) and 40 ng ml
-1
 GM-CSF 14 
(Peprotech) in low-adherence culture dishes. At day 5, all cells were collected by 15 
centrifugation, resuspended in the complete medium and seeded for experiments at 5x10
5
 16 
cells per well in a 24 well plate.  17 
The mouse melanoma cell line B16-OVA (kindly provided by K. Rock, University of 18 
Massachusetts Medical Center) and the T cell lymphoma E.G7-OVA (obtained from the 19 
American Type Culture Collection, Rockville, MD, USA) were cultured at 37°C in a 20 
humidified 5% CO2 atmosphere in RPMI 1640 medium (Sigma-Aldrich, Diegem, Belgium) 21 
supplemented with 10% FBS, 100 U ml
−1
 penicillin, 100 μg ml
−1
 streptomycin, 2 mM l-22 
glutamine and 0.4 mg ml
-1
 of the selection agent G418 (Thermo-Scientific, Aalst, Belgium).  23 
 31 
mRNA constructs 1 
Unmodified and nucleoside-modified (5meC, ) mRNA encoding firefly luciferase (fLuc) 2 
and the enhanced green fluorescent protein (eGFP) were purchased from TriLink (San Diego, 3 
CA). For the immunization studies, a truncated form of ovalbumin (tOVA) fused to the first 4 
80 amino acids of the invariant chain (Ii80) was produced by in vitro mRNA transcription 5 
from pGEM-Ii80tOVA plasmids.
72
 The in vitro transcription of mRNA and its subsequent 6 
quality control were performed as previously described.
31
 For the transcription of nucleoside-7 
modified mRNA, cytidine and uridine nucleotides were 100% replaced by 5-methylcytidine 8 
and pseudouridine (TriLink). 9 
mRNA lipid nanoparticle preparation 10 
DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) and cholesterol were purchased from 11 
Avanti Polar Lipids (Alabaster, USA). Alpha-Galactosylceramide (α-GC) and 6”-BODIPY-12 
analogue of α-GC were synthesized in house by S. Van Calenbergh. The synthesis of α-GC 13 
was performed as previously described.
73
 A detailed description of the preparation of 14 
BODIPY-labelled α-GC can be found in Supplementary Information. Cationic liposomes of 15 
DOTAP-cholesterol (2:3 molar ratio) were prepared by transferring the appropriate amounts 16 
of lipids, dissolved in chloroform into a round-bottom flask. For liposomes formulated with α-17 
GC, 0.5, 0.15, 0.015 or 0.0015 mol% of the total lipid amount was replaced by α-GC. The 18 
chloroform was evaporated under nitrogen, after which the lipid film was rehydrated in 19 
HEPES buffer (20 mM, pH 7.4, Sigma-Aldrich) to obtain a final lipid concentration of 20 
12.5 mM. The resulting cationic liposomes were sonicated until the dispersion became clear in 21 
a bath sonicator (Branson Ultrasonics, Dansbury, USA). Then, they were mixed with mRNA 22 
to obtain mRNA nanoparticles at a cationic lipid-to-mRNA (N/P) ratio of 3. mRNA 23 
 32 
nanoparticles for in vivo use were prepared in an isotonic HEPES buffer containing 5% 1 
glucose (Sigma-Aldrich).  2 
In vitro evaluation of ɑ-GC delivery and presentation by BM-DCs 3 
The in vitro experiments were performed on BM-DCs at day 6 of cell culture. The day before 4 
transfection, cells were seeded in 24 well plates at 5x10
5 
cells per well, and grown in the cell 5 
culture medium with 5% FCI serum. mRNA nanoparticles containing 0.5 mol% of α-GC were 6 
added directly to the cells in the complete cell culture medium (1 µg mRNA per 5x10
5
 cells). 7 
As a control, an equimolar dose of α-GC alone was added, dissolved in DMSO. To evaluate 8 
the presentation of α-GC in cell-surface CD1d complexes, BM-DCs cells were surface-stained 9 
with a monoclonal antibody specific for α-GC-CD1d complexes (clone L363, eBioscience). 10 
Flow analysis was performed 24h after the addition of mRNA nanoparticles (fLuc mRNA). 11 
Cells were collected and washed with PBS, stained with a fixable viability dye eFluor
®
 450 12 
(eBioscience) according to the manufacturer’s instructions, incubated with Fc block 13 
(CD16/32) to block non-specific FcR binding (BD Biosciences, Erembodegem, Belgium), and 14 
surface stained for CD11c-APC (clone N418) and α-GC:CD1d complex-PE for 30 min at 15 
4°C. Mouse IgG2a kappa PE antibody was used as isotype control for the presentation of α-16 
GC:CD1d. After additional washing steps, the cells were analysed by flow cytometry using a 17 
CytoFLEX (Beckman Coulter, Krefeld, Germany) and analysis was performed using FlowJo 18 
software (FlowJo, OR, USA). Confocal microscopy images of the cells were recorded using a 19 
Nikon C1si confocal laser scanning module attached to a motorized Nikon TE2000-E inverted 20 
microscope (Nikon Benelux, Brussels, Belgium), equipped with a Plan Apo 60x 1.0 NA oil 21 
immersion objective lens (Nikon).  22 
Administration of mRNA nanoparticles and an anti-PD-L1 antibody 23 
 33 
Mice were anesthetized in a ventilated anesthesia chamber with 3% isoflurane in oxygen. 1 
Prior to injection, a catheter of polyethylene tubing (Intramedic PE10, BD) containing sterile 2 
0.9% NaCl solution was inserted in the tail vein. After correct placement, nanoparticles with 3 
the indicated cargo diluted in sterile 5% glucose HEPES buffer were slowly injected (200 µl). 4 
A dose of 10 µg mRNA per mouse was chosen based on previous mRNA dose-optimization 5 
studies. The optimized dose of nanoparticle-encapsulated α-GC was 20 ng per mouse (0.015 6 
mol%), determined based on cytokine production and iNKT activation. Anti-PD-L1 antibody 7 
(10F.9G2, Bio X cell, West Lebanon, USA) or rat IgG2b isotype control antibody (LTF-2, 8 
Bio X cell) was administered i.p. at a dose of 100 µg, immediately after the administration of 9 
mRNA nanoparticles.  10 
Bioluminescence imaging 11 
Six hours after the injection of nanoparticles containing fLuc mRNA (TriLink), mice were 12 
anesthetized and abdomen and chest were depilated with hair removal cream. Subsequently, 13 
VivoGlo™ Luciferin (Promega) was administered i.p. in a volume of 100 µl (33 mg ml
-1
) per 14 
mouse. After 10 min, bioluminescence images were acquired by the IVIS lumina II system 15 
(PerkinElmer, Waltham, MA), and quantitative analysis of the images was performed using 16 
the Living Image software (PerkinElmer).  17 
Therapeutic vaccination experiments 18 
The therapeutic potential of mRNA nanoparticles (containing different cargo, or in 19 
combination with an anti-PD-L1 antibody) was evaluated by performing therapeutic 20 
vaccinations in tumor-bearing mice. For this, C57BL/6 received a s.c. injection of 3x10
5
 B16-21 
OVA or E.G7-OVA tumor cells (suspended in PBS) in the flank. Eight days after tumor 22 
inoculation, when the lesions were palpable, the mice were randomized in different treatment 23 
groups based on tumor volume, and vaccinated with mRNA nanoparticles. In some 24 
 34 
experiments, animals received a second and third therapeutic vaccination, every four or five 1 
days. Tumor growth was measured every other day or two days using a digital caliper. When 2 
the tumor volume exceeded 1000 mm
3
 (B16-OVA) or 1500 mm
3
 (E.G7-OVA), the mice were 3 
euthanized via cervical dislocation. 4 
Flow cytometric analysis on single cell suspensions 5 
At different time points after immunization, mice were euthanized and spleen, lungs, liver and 6 
tumors were harvested and processed into single cell suspensions as previously described.
31
 7 
Single cell suspensions were stained with either a fixable viability dye eFluor
®
 450 (Thermo 8 
Scientific) or Zombie Yellow™ (Biolegend, San Diego, CA) according to the manufacturer’s 9 
instructions to exclude dead cells from analysis, incubated with Fc block (CD16/32) to block 10 
non-specific FcR binding (BD Biosciences, Erembodegem, Belgium), and surface stained 11 
with the indicated antibodies during 30 min at 4°C (all Thermo-Scientific). After additional 12 
washing steps, the cells were analyzed by flow cytometry. Compensation for spectral overlap 13 
was calculated using UltraComp eBeads™ Compensation Beads (Thermo-Scientific) stained 14 
with individual fluorochrome-conjugated antibodies. 15 
The activation state of DC positive for CD11c-(APC or FITC) in the spleen was analysed by 16 
measuring the up-regulation of the co-stimulatory molecules CD40-FITC (HM40-3), CD86-17 
FITC (CL1), CD80-PE/Cy7 (16-10A1), and the inhibitory molecule PD-L1-Super Bright 436 18 
(MIH5). T cells were stained with monoclonal antibodies, including CD3e-PE (145-2C11), 19 
CD4-FITC (GK1.5), CD8a-(APC or AF488) (53-6.7) and PD-1-(efl450 or FITC) (RMP1-30). 20 
To stain OVA-specific T cells, an BV450-conjugated H-2Kb/SIINFEKL tetramer (OVA-21 
tetramer) was used, obtained from the National Institutes of Health (NIH) Tetramer Core 22 
Facility. iNKT cells were stained with TCR-APC (H57-597), PD1-efl450 and mCD1d PBS-23 
57 PE tetramer obtained from the NIH tetramer Core Facility. NK cells were detected using 24 
 35 
CD3e-PE (negative gating) and NK1.1-APC (PK136) staining. In addition, myeloid derived 1 
suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) were stained with 2 
antibodies including, CD11b-PE/Dazzle
TM
 594 (Biolegend), MHC-II-efl450 (M5/114.15.2), 3 
F4/80-(FITC or AF700) (6F12), Ly-6G/Ly-6C-FITC (RB6-8C5) and CD206-APC (C068C2). 4 
DCs (CD11c
+
) and tumor cells (CD45-PerCP-Cy5.5 negative cells) were evaluated for the 5 
expression of PD-L1.  6 
Cytokine measurements and alanine transaminase (ALT) activity 7 
Serum was collected 6h after i.v. injection of the mRNA nanoparticles and samples were 8 
stored at -80°C. Mouse Platinum IFN alpha ELISA kit , IFN- and IL-4 ELISA kits (Ready-9 
SET-Go!
®
) were purchased from Thermo-Scientific. A panel of 13 other cytokines, including 10 
IL-1α, IL-1β, IL-6, IL-10, IL-12p70, IL-17A, IL-23, IL-27, MCP-1, IFN-β, IFN-γ, TNF-α, 11 
and GM-CSF, was quantified using a multiplex assay (LEGENDplex™ Mouse Inflammation 12 
Panel, Biolegend). ALT enzyme activity was measured using a colometric assay kit 13 
(MaxDiscovery™, Bioo Scientific Corporation, Austin, USA). All assays were performed 14 
according to the manufacturer’s instructions.  15 
Statistical analysis 16 
All data are presented as mean ± standard deviation. Presented data of the in vitro 17 
experiments are representative for at least 3 independent experiments performed on three 18 
different days. The in vivo experiments contain data of at least two experiments merged into a 19 
single graph, this is explicitly mentioned in the figure caption. All statistical analysis were 20 
performed using GraphPad Prism6 (La Jolla, CA, USA). Information on the analysis per 21 
(sub)figure, is specified in the figure caption.  22 
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Supporting Information.  1 
The following files are available free of charge. Supplementary figures showing the uptake of 2 
BODIPY-a-GC by BM-DCs, when formulated in mRNA Galsomes or dissolved in DMSO, 3 
the transfection capacity of mRNA Galsomes in BM-DCs and human monocyted-derived 4 
DCs, the adjuvant effect of mRNA Galsomes on BM-DCs in vitro, the toxicity evaluation of 5 
mRNA Galsomes in monotherapy and combined with an anti-PD-L1 antibody, the tumor 6 
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